Search Results - "Hiromitsu Kumada"

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset by Yamashita, Tatsuya, Kudo, Masatoshi, Ikeda, Kenji, Izumi, Namiki, Tateishi, Ryosuke, Ikeda, Masafumi, Aikata, Hiroshi, Kawaguchi, Yasunori, Wada, Yoshiyuki, Numata, Kazushi, Inaba, Yoshitaka, Kuromatsu, Ryoko, Kobayashi, Masahiro, Okusaka, Takuji, Tamai, Toshiyuki, Kitamura, Chifumi, Saito, Kenichi, Haruna, Katsuya, Okita, Kiwamu, Kumada, Hiromitsu

“…Background A phase 3, multinational, randomized, non-inferiority trial (REFLECT) compared the efficacy and safety of lenvatinib (LEN) and sorafenib (SOR) in…”
Get full text

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma by Ikeda, Kenji, Kudo, Masatoshi, Kawazoe, Seiji, Osaki, Yukio, Ikeda, Masafumi, Okusaka, Takuji, Tamai, Toshiyuki, Suzuki, Takuya, Hisai, Takashi, Hayato, Seiichi, Okita, Kiwamu, Kumada, Hiromitsu

“…Background Lenvatinib is an oral inhibitor of vascular endothelial growth factor receptor 1–3, fibroblast growth factor receptor 1–4, platelet-derived growth…”
Get full text

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study by Tateishi, Ryosuke, Okanoue, Takeshi, Fujiwara, Naoto, Okita, Kiwamu, Kiyosawa, Kendo, Omata, Masao, Kumada, Hiromitsu, Hayashi, Norio, Koike, Kazuhiko

“…Background The number of hepatocellular carcinoma (HCC) patients with non-viral etiologies is increasing in Japan. We conducted a nation-wide survey to examine…”
Get full text

Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma by Finkin, Shlomi, Yuan, Detian, Stein, Ilan, Taniguchi, Koji, Weber, Achim, Unger, Kristian, Browning, Jeffrey L, Goossens, Nicolas, Nakagawa, Shigeki, Gunasekaran, Ganesh, Schwartz, Myron E, Kobayashi, Masahiro, Kumada, Hiromitsu, Berger, Michael, Pappo, Orit, Rajewsky, Klaus, Hoshida, Yujin, Karin, Michael, Heikenwalder, Mathias, Ben-Neriah, Yinon, Pikarsky, Eli

“…Ectopic lymphoid structures develop at sites of chronic inflammation and are generally thought to be beneficial in the control of cancer. Pikarsky and…”
Get full text

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus by Akuta, Norio, Kawamura, Yusuke, Watanabe, Chizuru, Nishimura, Akihiro, Okubo, Minoru, Mori, Yasumichi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Aim The aim of this study was to investigate the therapeutic potential of sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective therapeutic option…”
Get full text

Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double‐blind trial by Kumada, Hiromitsu, Miyakawa, Hiroshi, Muramatsu, Taro, Ando, Naoki, Oh, Takanori, Takamori, Kenji, Nakamoto, Hidetomo

“…Aims Patients with chronic liver disease sometimes develop cholestasis, which induces severe whole‐body pruritus that may disrupt daily activities and sleep…”
Get full text

Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients by Suzuki, Fumitaka, Miyakoshi, Hideo, Kobayashi, Mariko, Kumada, Hiromitsu

“…Nucleos(t)ide analogues are utilized for the treatment of chronic HBV infection, and HBe seroconversion and HBV DNA levels are commonly used as markers of…”
Get full text

Molecular Liver Cancer Prevention in Cirrhosis by Organ Transcriptome Analysis and Lysophosphatidic Acid Pathway Inhibition by Nakagawa, Shigeki, Wei, Lan, Song, Won Min, Higashi, Takaaki, Ghoshal, Sarani, Kim, Rosa S., Bian, C. Billie, Yamada, Suguru, Sun, Xiaochen, Venkatesh, Anu, Goossens, Nicolas, Bain, Gretchen, Lauwers, Gregory Y., Koh, Anna P., El-Abtah, Mohamed, Ahmad, Noor B., Hoshida, Hiroki, Erstad, Derek J., Gunasekaran, Ganesh, Lee, Youngmin, Yu, Ming-Lung, Chuang, Wan-Long, Dai, Chia-Yen, Kobayashi, Masahiro, Kumada, Hiromitsu, Beppu, Toru, Baba, Hideo, Mahajan, Milind, Nair, Venugopalan D., Lanuti, Michael, Villanueva, Augusto, Sangiovanni, Angelo, Iavarone, Massimo, Colombo, Massimo, Llovet, Josep M., Subramanian, Aravind, Tager, Andrew M., Friedman, Scott L., Baumert, Thomas F., Schwarz, Myron E., Chung, Raymond T., Tanabe, Kenneth K., Zhang, Bin, Fuchs, Bryan C., Hoshida, Yujin

“…Cirrhosis is a milieu that develops hepatocellular carcinoma (HCC), the second most lethal cancer worldwide. HCC prediction and prevention in cirrhosis are key…”
Get full text

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study by Kumada, Hiromitsu, Suzuki, Yoshiyuki, Karino, Yoshiyasu, Chayama, Kazuaki, Kawada, Norifumi, Okanoue, Takeshi, Itoh, Yoshito, Mochida, Satoshi, Toyoda, Hidenori, Yoshiji, Hitoshi, Takaki, Shintaro, Yatsuzuka, Naoyoshi, Yodoya, Etsuo, Iwasa, Takashi, Fujimoto, Go, Robertson, Michael N., Black, Stuart, Caro, Luzelena, Wahl, Janice

“…Background Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials…”
Get full text

Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma by HOSHIDA, Yujin, NIJMAN, Sebastian M. B, WATANABE, Goro, GABRIEL, Stacey, FRIEDMAN, Scott L, KUMADA, Hiromitsu, LLOVET, Josep M, GOLUB, Todd R, KOBAYASHI, Masahiro, CHAN, Jennifer A, BRUNET, Jean-Philippe, CHIANG, Derek Y, VILLANUEVA, Augusto, NEWELL, Philippa, IKEDA, Kenji, HASHIMOTO, Masaji

“…Hepatocellular carcinoma (HCC) is a highly heterogeneous disease, and prior attempts to develop genomic-based classification for HCC have yielded highly…”
Get full text

SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology by Akuta, Norio, Kawamura, Yusuke, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu

“…Objective The aim of this study was to determine the long-term effects of a sodium-glucose cotransporter 2 inhibitor (SGLT2i) in nonalcoholic fatty liver…”
Get full text

Direct-Acting Antivirals Decreased Tumor Recurrence After Initial Treatment of Hepatitis C Virus-Related Hepatocellular Carcinoma by Ikeda, Kenji, Kawamura, Yusuke, Kobayashi, Masahiro, Kominami, Yoko, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Kumada, Hiromitsu

“…Background Suppressive activity of recurrence by interferon-free direct-acting antivirals (DAA) is not elucidated after curative treatment of hepatocellular…”
Get full text

Efficacy and safety of glecaprevir/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection by Kumada, Hiromitsu, Watanabe, Tsunamasa, Suzuki, Fumitaka, Ikeda, Kenji, Sato, Ken, Toyoda, Hidenori, Atsukawa, Masanori, Ido, Akio, Takaki, Akinobu, Enomoto, Nobuyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David, Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, Chayama, Kazuaki

“…Background Once-daily, orally administered, co-formulated glecaprevir (NS3/4A protease inhibitor) and pibrentasvir (NS5A inhibitor) (G/P) demonstrated…”
Get full text

Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular Carcinoma by Villanueva, Augusto, Hoshida, Yujin, Battiston, Carlo, Tovar, Victoria, Sia, Daniela, Alsinet, Clara, Cornella, Helena, Liberzon, Arthur, Kobayashi, Masahiro, Kumada, Hiromitsu, Thung, Swan N, Bruix, Jordi, Newell, Philippa, April, Craig, Fan, Jian–Bing, Roayaie, Sasan, Mazzaferro, Vincenzo, Schwartz, Myron E, Llovet, Josep M

“…Background & Aims In approximately 70% of patients with hepatocellular carcinoma (HCC) treated by resection or ablation, disease recurs within 5 years…”
Get full text

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis by Chayama, Kazuaki, Suzuki, Fumitaka, Karino, Yoshiyasu, Kawakami, Yoshiiku, Sato, Ken, Atarashi, Tomofumi, Naganuma, Atsushi, Watanabe, Tsunamasa, Eguchi, Yuichiro, Yoshiji, Hitoshi, Seike, Masataka, Takei, Yoshiyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David L., Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, Kumada, Hiromitsu

“…Background The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir…”
Get full text

Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study by Okanoue, Takeshi, Sakamoto, Michiie, Harada, Kenichi, Inagaki, Masaya, Totsuka, Naoko, Hashimoto, Gaia, Kumada, Hiromitsu

“…Aim To evaluate the efficacy, safety, and tolerability of apararenone 10 mg/day in patients with nonalcoholic steatohepatitis (NASH). Methods In this…”
Get full text

The useful predictors of zinc deficiency for the management of chronic liver disease by Iritani, Soichi, Kawamura, Yusuke, Muraishi, Nozomu, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Saitoh, Satoshi, Suzuki, Fumitaka, Arase, Yasuji, Ikeda, Kenji, Suzuki, Yoshiyuki, Kumada, Hiromitsu

“…Background Zinc deficiency is likely to occur in chronic liver disease. The aim of this study was to determine the prevalence of zinc deficiency in different…”
Get full text

Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma by Hoshida, Yujin, Villanueva, Augusto, Kobayashi, Masahiro, Peix, Judit, Chiang, Derek Y, Camargo, Amy, Gupta, Supriya, Moore, Jamie, Wrobel, Matthew J, Lerner, Jim, Reich, Michael, Chan, Jennifer A, Glickman, Jonathan N, Ikeda, Kenji, Hashimoto, Masaji, Watanabe, Goro, Daidone, Maria G, Roayaie, Sasan, Schwartz, Myron, Thung, Swan, Salvesen, Helga B, Gabriel, Stacey, Mazzaferro, Vincenzo, Bruix, Jordi, Friedman, Scott L, Kumada, Hiromitsu, Llovet, Josep M, Golub, Todd R

“…The authors have established a method for the analysis of gene expression in tissue specimens preserved in formaldehyde. The expression profile of tissue…”
Get full text

Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients by Ono, Atsushi, Suzuki, Fumitaka, Kawamura, Yusuke, Sezaki, Hitomi, Hosaka, Tetsuya, Akuta, Norio, Kobayashi, Masahiro, Suzuki, Yoshiyuki, Saitou, Satoshi, Arase, Yasuji, Ikeda, Kenji, Kobayashi, Mariko, Watahiki, Sachiyo, Mineta, Rie, Kumada, Hiromitsu

“…Background & Aims We determined the antiviral potency and viral resistance rate after 4 years of continuous entecavir treatment in patients with chronic…”
Get full text

Integrated Resistance Analysis of CERTAIN-1 and CERTAIN-2 Studies in Hepatitis C Virus-Infected Patients Receiving Glecaprevir and Pibrentasvir in Japan by Krishnan, Preethi, Schnell, Gretja, Tripathi, Rakesh, Beyer, Jill, Reisch, Thomas, Dekhtyar, Tatyana, Irvin, Michelle, Xie, Wangang, Fu, Bo, Burroughs, Margaret, Redman, Rebecca, Kumada, Hiromitsu, Chayama, Kazuaki, Collins, Christine, Pilot-Matias, Tami

“…Glecaprevir and pibrentasvir are hepatitis C virus (HCV) pangenotypic inhibitors targeting NS3/4A protease and NS5A, respectively. This once-daily, fixed-dose…”
Get full text